Medical Specialties List: Find Your Profession | Healthcare Fields

Cardiomyopathy, a disease of the heart muscle, is increasingly being recognized as a significant complication for individuals living with HIV, according to a recent comprehensive review published in Frontiers in Cardiovascular Medicine. The study, released in September 2025, details the molecular mechanisms, clinical presentations, and potential treatment strategies for HIV-associated cardiomyopathy.

Historically, as treatments for HIV have improved and lifespans have extended, clinicians have observed a rise in non-infectious complications, including cardiovascular disease. Research published in 2009 in Clinical Cardiology noted that as more effective HIV therapies emerged, heart disease began to appear as a late-stage complication. This trend is now being more closely examined at a molecular level.

The recent review highlights the complex interplay between HIV and the heart, noting that the virus can impact cardiac function through multiple pathways. Researchers from institutions including Northwestern University and the University of Ibadan College of Medicine, among others, collaborated on the study. They emphasize the need for increased awareness and proactive diagnostic approaches.

Atherosclerotic vascular disease is disproportionately affecting people living with HIV (PLWH) compared to those without the virus, according to research published in PubMed. This increased risk is linked to dysregulated immune responses and inflammation related to HIV infection, as well as co-morbidities and co-infections.

The pathogenesis of HIV-associated cardiomyopathy involves a complex interplay of factors, including viral products, soluble mediators, chemokines, and both innate and adaptive immune cells. The review as well points to the role of co-infections, such as cytomegalovirus, varicella zoster virus, and hepatitis C virus, in exacerbating cardiovascular risk.

Advances in cardiac imaging and immunology are contributing to a deeper understanding of the mechanisms driving HIV-associated cardiovascular disease, as noted by the American Heart Association. However, the review suggests that further research is needed to identify effective therapeutic targets and reduce cardiovascular risk in PLWH.

The study authors have not yet announced specific clinical trial plans or policy recommendations stemming from their findings.